Choi JH, et al. - In this randomized, prospective, comparative study, researchers compared sorafenib to hepatic arterial infusion chemotherapy (HAIC) with in terms of efficacy and safety in treating advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) patients. Data on 58 such patients, with Child–Turcotte–Pugh (CTP) scores of 5-7, was gathered from six university hospitals between January 2013 and October 2015. Sorafenib was received by 29 patients and 29 patients were treated with HAIC. Based on the findings, they concluded that in the management of patients with advanced HCC with PVTT, HAIC may be a valuable treatment modality. Compared to the sorafenib group, median overall survival and time to progression were significantly longer in the HAIC group.